- In September 2024, AstraZeneca's FluMist Approved for Self-Administration in the US. This marks a significant advancement as it's the first flu vaccine that doesn't require administration by a healthcare provider, enhancing accessibility and convenience for individuals seeking influenza prevention. FluMist was approved by the US FDA for self-administration by adults up to 49 years of age or administered by a parent/caregiver to individuals 2-17 years of age
- In August 2024, Scientists from Harvard Medical School developed a nasal spray called the Pathogen Capture and Neutralizing Spray (PCANS), or Profi. This spray claims to protect against flu, colds, and COVID-19 with over 99.99% effectiveness by forming a barrier in the nasal cavity that captures and neutralizes viruses and bacteria
- In May 2024, Sanofi and Novavax announced a co-exclusive licensing agreement to co-commercialize Novavax's current stand-alone adjuvanted COVID-19 vaccine worldwide and develop a novel influenza-COVID-19 vaccine combination. This partnership aims to accelerate the development of combined vaccines, offering enhanced convenience and protection for patients.
- In April 2023, Sinovac Biotech Co., Ltd. announced the recent commissioning of its new influenza vaccine manufacturing facility in Beijing. This expansion increases global production capacity for influenza vaccines, contributing to broader availability and supply
- In March 2023, The FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) convened to determine the vaccine's composition for the U.S. 2023-2024 influenza season. This annual process is crucial for ensuring that the vaccines are effective against the circulating strains of influenza viruses.
